BOUQUEGNEAU, Antoine ; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Service de néphrologie
Loheac, C.; Paris Translational Research Center for Organ Transplantation INSERM Unit 970, Paris, France
Aubert, O.; Paris Translational Research Center for Organ Transplantation INSERM Unit 970, Paris, France, Department of Kidney Transplantation, Necker Hospital, Paris Descartes University and Assistance Publique–Hôpitaux de Paris (AP–HP), Paris, France
Bouatou, Y.; Paris Translational Research Center for Organ Transplantation INSERM Unit 970, Paris, France, Division of Nephrology, Geneva University Hospitals, Geneva, Switzerland
Viglietti, D.; Paris Translational Research Center for Organ Transplantation INSERM Unit 970, Paris, France, Department of Nephrology and Kidney Transplantation, Saint–Louis Hospital, Paris Diderot University, AP–HP, Paris, France
Empana, J. P.; Paris Translational Research Center for Organ Transplantation INSERM Unit 970, Paris, France
Ulloa, C.; Hospital Barros Luco Trudeau, Santiago et Clinica Alemana de Santiago, Chile
Hassan Murad, M.; Mayo Clinic Evidence–based Practice Center, Mayo Clinic, Rochester, MN, United States
Legendre, C.; Paris Translational Research Center for Organ Transplantation INSERM Unit 970, Paris, France, Department of Kidney Transplantation, Necker Hospital, Paris Descartes University and Assistance Publique–Hôpitaux de Paris (AP–HP), Paris, France
Glotz, D.; Paris Translational Research Center for Organ Transplantation INSERM Unit 970, Paris, France, Department of Nephrology and Kidney Transplantation, Saint–Louis Hospital, Paris Diderot University, AP–HP, Paris, France
Jackson, A. M.; Immunogenetics Laboratory, Johns Hopkins University School of Medicine, Baltimore, MD, United States
Zeevi, A.; Department of Pathology, Surgery and Immunology at University of Pittsburgh Medical Center, Pittsburgh, PA, United States
Schaub, S.; Clinic for Transplantation Immunology and Nephrology, University Hospital Basel, Basel, Switzerland
Taupin, J. L.; Department of Immunology and Histocompatibility, CHU Paris–GH St–Louis Lariboisière, Paris, France
Reed, E. F.; Department of Pathology and Laboratory Medicine, UCLA Immunogenetics Center, David Geffen School of Medicine, University of California, Los Angeles, CA, United States
Friedewald, J. J.; Northwestern University Feinberg School of Medicine, Comprehensive Transplant Center, Division of Transplant Surgery, Chicago, IL, United States
Tyan, D. B.; Division of Nephrology, Department of Medicine, Stanford University, Stanford, CA, United States
Süsal, C.; Institute of Immunology, Heidelberg University, Department of Transplantation Immunology, Heidelberg, Germany
Shapiro, R.; Kidney/Pancreas Transplant Program, Mount Sinai Hospital, Recanati Miller Transplantation Institute, New York, NY, United States
Woodle, E. S.; Division of Transplantation, Department of Surgery and Division of Hematology and Oncology, Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, OH, United States
Hidalgo, L. G.; Department of Laboratory Medicine and Pathology and Alberta Transplant Applied Genomics Center, Edmonton, AB, Canada
O’Leary, J.; Annette C. & Harold C. Simmons Transplant Institute, Baylor University Medical Center, Dallas, TX, United States
Montgomery, R. A.; The NYU Transplant Institute, New York University Langone Medical Center, New York, NY, United States
Kobashigawa, J.; Cedars–Sinai Heart Institute, Los Angeles, CA, United States
Jouven, X.; Paris Translational Research Center for Organ Transplantation INSERM Unit 970, Paris, France, Department of Cardiology and Global Health Unit European Georges Pompidou Hospital, Paris, France
Jabre, P.; Paris Translational Research Center for Organ Transplantation INSERM Unit 970, Paris, France, SAMU of Paris, Necker Hospital, Paris, France, Paris Descartes University, Paris, France, AP–HP, Paris, France
Lefaucheur, C.; Paris Translational Research Center for Organ Transplantation INSERM Unit 970, Paris, France, Department of Nephrology and Kidney Transplantation, Saint–Louis Hospital, Paris Diderot University, AP–HP, Paris, France
Loupy, A.; Paris Translational Research Center for Organ Transplantation INSERM Unit 970, Paris, France, Department of Kidney Transplantation, Necker Hospital, Paris Descartes University and Assistance Publique–Hôpitaux de Paris (AP–HP), Paris, France
Port FK, Wolfe RA, Mauger EA, Berling DP, Jiang K, Comparison of survival probabilities for dialysis patients vs cadaveric renal transplant recipients. JAMA. 1993;270: 1339–1343. 8360969
Stehlik J, Edwards LB, Kucheryavaya AY, Benden C, Christie JD, Dobbels F, et al. The Registry of the International Society for Heart and Lung Transplantation: Twenty–eighth Adult Heart Transplant Report––2011. J Heart Lung Transplant. 2011;30: 1078–1094. doi: 10.1016/j.healun.2011.08.003 21962016
Organ Procurement and Transplantation Network: Scientific registry of transplant recipients. [Cited 1 January 2018]. Available from: http://optn.transplant.hrsa.gov/data/.
Eurotransplant Annual Report. [Cited 1 January 2018]. Available from: https://www.eurotransplant.org/cms/index.php?page=annual_reports.
Nankivell BJ, Alexander SI, Rejection of the kidney allograft. N Engl J Med. 2010;363: 1451–1462. doi: 10.1056/NEJMra0902927 20925547
Mohan S, Palanisamy A, Tsapepas D, Tanriover B, Crew RJ, Dube G, et al. Donor-specific antibodies adversely affect kidney allograft outcomes. J Am Soc Nephrol. 2012;23: 2061–2071. doi: 10.1681/ASN.2012070664 23160511
Smith JD, Banner NR, Hamour IM, Ozawa M, Goh A, Robinson D, et al. De novo donor HLA–specific antibodies after heart transplantation are an independent predictor of poor patient survival. Am J Transplant. 2011;11: 312–319. doi: 10.1111/j.1600-6143.2010.03383.x 21219570
Kaneku H, O’Leary JG, Banuelos N, Jennings LW, Susskind BM, Klintmalm GB, et al. De novo donor-specific HLA antibodies decrease patient and graft survival in liver transplant recipients. Am J Transplant. 2013;13: 1541–1548. doi: 10.1111/ajt.12212 23721554
Lefaucheur C, Loupy A, Hill GS, Andrade J, Nochy D, Antoine C, et al. Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation. J Am Soc Nephrol. 2010;21: 1398–1406. doi: 10.1681/ASN.2009101065 20634297
Morrell MR, Pilewski JM, Gries CJ, Pipeling MR, Crespo MM, Ensor CR, et al. De novo donor-specific HLA antibodies are associated with early and high–grade bronchiolitis obliterans syndrome and death after lung transplantation. J Heart Lung Transplant. 2014;33: 1288–1294. doi: 10.1016/j.healun.2014.07.018 25443870
Ho EK, Vlad G, Vasilescu ER, de la Torre L, Colovai AI, Burke E, et al. Pre–and posttransplantation allosensitization in heart allograft recipients: major impact of de novo alloantibody production on allograft survival. Hum Immunol. 2011;72: 5–10. doi: 10.1016/j.humimm.2010.10.013 20971146
O’Leary JG, Kaneku H, Susskind BM, Jennings LW, Neri MA, Davis GL, et al. High mean fluorescence intensity donor-specific anti-HLA antibodies associated with chronic rejection post liver transplant. Am J Transplant. 2011;11: 1868–1876. doi: 10.1111/j.1600-6143.2011.03593.x 21672151
Cheng EY, Everly MJ, Kaneku H, Banuelos N, Wozniak LJ, Venick RS, et al. Prevalence and clinical impact of donor-specific alloantibody among intestinal transplant recipients. Transplantation. 2017;101: 873–882. doi: 10.1097/TP.0000000000001391 27490417
Mittal S, Page SL, Friend PJ, Sharples EJ, Fuggle SV, De novo donor-specific HLA antibodies: Biomarkers of pancreas transplant failure. Am J Transplant. 2014;14: 1664–1671. doi: 10.1111/ajt.12750 24866735
Loupy A, Lefaucheur C, Vernerey D, Prugger C, Duong van Huyen J–P, Mooney N, et al. Complement–binding anti-HLA antibodies and kidney–allograft survival. N Engl J Med. 2013;369: 1215–1226. doi: 10.1056/NEJMoa1302506 24066742
Sicard A, Ducreux S, Rabeyrin M, Couzi L, McGregor B, Badet L, et al. Detection of C3d–binding donor-specific anti-HLA antibodies at diagnosis of humoral rejection predicts renal graft loss. J Am Soc Nephrol. 2015;26: 457–467. doi: 10.1681/ASN.2013101144 25125383
Calp–Inal S, Ajaimy M, Melamed ML, Savchik C, Masiakos P, Colovai A, et al. The prevalence and clinical significance of C1q–binding donor-specific anti-HLA antibodies early and late after kidney transplantation. Kidney Int. 2016;89: 209–216. doi: 10.1038/ki.2015.275 26535999
Guidicelli G, Guerville F, Lepreux S, Wiebe C, Thaunat O, Dubois V, et al. Non–Complement–Binding De Novo Donor-specific Anti-HLA Antibodies and Kidney Allograft Survival. J Am Soc Nephrol. 2016;27: 615–625. doi: 10.1681/ASN.2014040326 26047793
Comoli P, Cioni M, Tagliamacco A, Quartuccio G, Innocente A, Fontana I, et al. Acquisition of C3d–Binding Activity by De Novo Donor-specific HLA Antibodies Correlates With Graft Loss in Nonsensitized Pediatric Kidney Recipients. Am J Transplant. 2016;16: 2106–2116. doi: 10.1111/ajt.13700 26725780
Fichtner A, Süsal C, Höcker B, Rieger S, Waldherr R, Westhoff JH, et al. Association of C1q–fixing DSA with late graft failure in pediatric renal transplant recipients. Pediatr Nephrol. 2016;31: 1157–1166. doi: 10.1007/s00467-016-3322-8 26928311
Zeevi A, Lunz J, Feingold B, Shullo M, Bermudez C, Teuteberg J, et al. Persistent strong anti-HLA antibody at high titer is complement binding and associated with increased risk of antibody–mediated rejection in heart transplant recipients. J Heart Lung Transplant. 2013;32: 98–105. doi: 10.1016/j.healun.2012.09.021 23142561
Chin C, Chen G, Sequeria F, Berry G, Siehr S, Bernstein D, et al. Clinical usefulness of a novel C1q assay to detect immunoglobulin G antibodies capable of fixing complement in sensitized pediatric heart transplant patients. J Heart Lung Transplant. 2011;30: 158–163. doi: 10.1016/j.healun.2010.08.020 20951058
O’Leary JG, Kaneku H, Banuelos N, Jennings LW, Klintmalm GB, Terasaki PI, Impact of IgG3 subclass and C1q–fixing donor-specific HLA alloantibodies on rejection and survival in liver transplantation. Am J Transplant. 2015;15: 1003–1013. doi: 10.1111/ajt.13153 25772599
Smith JD, Ibrahim MW, Newell H, Danskine AJ, Soresi S, Burke MM, et al. Pre–transplant donor HLA–specific antibodies: characteristics causing detrimental effects on survival after lung transplantation. J Heart Lung Transplant. 2014;33: 1074–1082. doi: 10.1016/j.healun.2014.02.033 24954882
Wahrmann M, Bartel G, Exner M, Regele H, Körmöczi GF, Fischer GF, et al. Clinical relevance of preformed C4d–fixing and non–C4d–fixing HLA single antigen reactivity in renal allograft recipients. Transpl Int. 2009;22: 982–989. doi: 10.1111/j.1432-2277.2009.00912.x 19619171
Wiebe C, Gareau AJ, Pochinco D, Gibson IW, Ho J, Birk PE, et al. Evaluation of C1q Status and Titer of De Novo Donor-specific Antibodies as Predictors of Allograft Survival. Am J Transplant. 2017;17: 703–711. doi: 10.1111/ajt.14015 27539748
Hönger G, Wahrmann M, Amico P, Hopfer H, Böhmig GA, Schaub S, C4d–fixing capability of low–level donor-specific HLA antibodies is not predictive for early antibody–mediated rejection. Transplantation. 2010;89: 1471–1475. doi: 10.1097/TP.0b013e3181dc13e7 20395886
Yell M, Muth BL, Kaufman DB, Djamali A, Ellis TM, C1q Binding Activity of De Novo Donor-specific HLA Antibodies in Renal Transplant Recipients With and Without Antibody–mediated Rejection: Transplantation. 2015;99: 1151–1155. doi: 10.1097/TP.0000000000000699 25839705
Kauke T, Oberhauser C, Lin V, Coenen M, Fischereder M, Dick A, et al. De novo donorspecific anti-HLA antibodies after kidney transplantation are associated with impaired graft outcome independently of their C1q–binding ability. Transpl Int. 2017;30: 360–370. doi: 10.1111/tri.12887 27862352
Capital Reporting Company from the Food and Drug Administration. Surrogate Endpoints for Clinical Trials in Kidney Transplantation 28 September 2015. [Cited 1 January 2018]. Available from: https://www.fda.gov/downloads/Drugs/NewsEvents/UCM470429.pdf.
Transplant Therapeutics Consortium. [Cited 1 January 2018]. Available from: https://c-path.org/programs/ttc/.
Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta–analyses: the PRISMA statement. BMJ. 2009;339: b2535. doi: 10.1136/bmj.b2535 19622551
Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000;283: 2008–2012. 10789670
Guidicelli G, Anies G, Bachelet T, Dubois V, Moreau J– F, Merville P, et al. The complement interference phenomenon as a cause for sharp fluctuations of serum anti-HLA antibody strength in kidney transplant patients. Transpl Immunol. 2013;29: 17–21. doi: 10.1016/j.trim.2013.09.005 24056164
Tao MH, Smith RI, Morrison SL, Structural features of human immunoglobulin G that determine isotype–specific differences in complement activation. J Exp Med. 1993;178: 661–667. 8340761
Loupy A, Haas M, Solez K, Racusen L, Glotz D, Seron D, et al. The Banff 2015 Kidney Meeting Report: Current Challenges in Rejection Classification and Prospects for Adopting Molecular Pathology. Am J Transplant. 2017;17: 28–41. doi: 10.1111/ajt.14107 27862883
Demetris A, Adams D, Bellamy C, Blakolmer K, Clouston A, Dhillon AP, et al. Update of the International Banff Schema for Liver Allograft Rejection: working recommendations for the histopathologic staging and reporting of chronic rejection. An International Panel. Hepatology. 2000;31: 792–799. doi: 10.1002/hep.510310337 10706577
Berry GJ, Angelini A, Burke MM, Bruneval P, Fishbein MC, Hammond E, et al. The ISHLT working formulation for pathologic diagnosis of antibody–mediated rejection in heart transplantation: evolution and current status (2005–2011). J Heart Lung Transplant. 2011;30: 601–611. doi: 10.1016/j.healun.2011.02.015 21555100
Wells GA, Shea B, O’Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle–Ottawa Scale (NOS) for assessing the quality of non–randomised studies in meta–analyses. [Cited 1 January 2018]. Available from: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.
Nikolakopoulou A, Mavridis D, Salanti G, How to interpret meta-analysis models: fixed effect and random effects meta–analyses. Evid Based Ment Health. 2014;17: 64. doi: 10.1136/eb-2014-101794 24778439
Higgins JPT, Thompson SG, Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21: 1539–1558. doi: 10.1002/sim.1186 12111919
Egger M, Davey Smith G, Schneider M, Minder C, Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315: 629–634. 9310563
Thompson SG, Higgins JPT, How should meta–regression analyses be undertaken and interpreted?Stat Med. 2002;21: 1559–1573. doi: 10.1002/sim.1187 12111920
Harbord RM, Higgins JPT, Meta–regression in Stata. Stata J. 2008;4: 493–519.
McPheeters ML, Kripalani S, Peterson NB, Idowu RT, Jerome RN, Potter SA, et al. Closing the quality gap: revisiting the state of the science (vol. 3: quality improvement interventions to address health disparities). Evid ReportTechnology Assess. 2012;208.3: 1–475.
Lefaucheur C, Viglietti D, Bentlejewski C, Huyen J–PD van, Vernerey D, Aubert O, et al. IgG Donor-specific Anti–Human HLA Antibody Subclasses and Kidney Allograft Antibody–Mediated Injury. J Am Soc Nephrol. 2016;27: 293–304. doi: 10.1681/ASN.2014111120 26293822
Viglietti D, Loupy A, Vernerey D, Bentlejewski C, Gosset C, Aubert O, et al. Value of Donor-specific Anti-HLA Antibody Monitoring and Characterization for Risk Stratification of Kidney Allograft Loss. J Am Soc Nephrol. 2017;28: 702–715. doi: 10.1681/ASN.2016030368 27493255
Sutherland SM, Chen G, Sequeira FA, Lou CD, Alexander SR, Tyan DB, Complement–fixing donor-specific antibodies identified by a novel C1q assay are associated with allograft loss. Pediatr Transplant. 2012;16: 12–17. doi: 10.1111/j.1399-3046.2011.01599.x 22093755
Hönger G, Hopfer H, Arnold M–L, Spriewald BM, Schaub S, Amico P, Pretransplant IgG subclasses of donor-specific human leukocyte antigen antibodies and development of antibody–mediated rejection. Transplantation. 2011;92: 41–47. doi: 10.1097/TP.0b013e31821cdf0d 21637140
Kaneku H, O’Leary JG, Taniguchi M, Susskind BM, Terasaki PI, Klintmalm GB, Donor-specific human leukocyte antigen antibodies of the immunoglobulin G3 subclass are associated with chronic rejection and graft loss after liver transplantation. Liver Transpl. 2012;18: 984–992. doi: 10.1002/lt.23451 22508525
Bartel G, Wahrmann M, Schwaiger E, Kikic Z, Winzer C, Horl WH, et al. Solid phase detection of C4d–fixing HLA antibodies to predict rejection in high immunological risk kidney transplant recipients. Transpl Int. 2013;26: 121–30. doi: 10.1111/tri.12000 23145861
Lawrence C, Willicombe M, Brookes PA, Santos–Nunez E, Bajaj R, Cook T, et al. Preformed complement-activating low–level donor-specific antibody predicts early antibody–mediated rejection in renal allografts. Transplantation. 2013;95: 341–346. doi: 10.1097/TP.0b013e3182743cfa 23197178
Crespo M, Torio A, Mas V, Redondo D, Pérez–Sáez MJ, Mir M, et al. Clinical relevance of pretransplant anti-HLA donor-specific antibodies: does C1q–fixation matter?Transpl Immunol. 2013;29: 28–33. doi: 10.1016/j.trim.2013.07.002 23907088
Freitas MCS, Rebellato LM, Ozawa M, Nguyen A, Sasaki N, Everly M, et al. The role of immunoglobulin–G subclasses and C1q in de novo HLA–DQ donor-specific antibody kidney transplantation outcomes. Transplantation. 2013;95: 1113–1119. doi: 10.1097/TP.0b013e3182888db6 23514959
Arnold M–L, Ntokou I–S, Doxiadis IIN, Spriewald BM, Boletis JN, Iniotaki AG, Donor-specific HLA antibodies: evaluating the risk for graft loss in renal transplant recipients with isotype switch from complement fixing IgG1/IgG3 to noncomplement fixing IgG2/IgG4 anti-HLA alloantibodies. Transpl Int. 2014;27: 253–61. doi: 10.1111/tri.12206 24118579
Everly MJ, Rebellato LM, Haisch CE, Briley KP, Bolin P, Kendrick WT, et al. Impact of IgM and IgG3 anti-HLA alloantibodies in primary renal allograft recipients. Transplantation. 2014;97: 494–501. doi: 10.1097/01.TP.0000441362.11232.48 24487396
Wozniak LJ, Hickey MJ, Venick RS, Vargas JH, Farmer DG, Busuttil RW, et al. Donor-specific HLA Antibodies Are Associated With Late Allograft Dysfunction After Pediatric Liver Transplantation. Transplantation. 2015;99: 1416–22. doi: 10.1097/TP.0000000000000796 26038872
Khovanova N, Daga S, Shaikhina T, Krishnan N, Jones J, Zehnder D, et al. Subclass analysis of donor HLA–specific IgG in antibody–incompatible renal transplantation reveals a significant association of IgG4 with rejection and graft failure. Transpl Int. 2015;28: 1405–1415. doi: 10.1111/tri.12648 26264744
Thammanichanond D, Wiwattanathum P, Mongkolsuk T, Kantachuvesiri S, Worawichawong S, Vallipakorn SA, et al. Role of Pretransplant Complement–fixing Donor-specific Antibodies Identified by C1q Assay in Kidney Transplantation. Transplant Proc. 2016;48: 756–760. doi: 10.1016/j.transproceed.2015.12.116 27234729
Yamamoto T, Watarai Y, Takeda A, Tsujita M, Hiramitsu T, Goto N, et al. De Novo Anti-HLA DSA Characteristics and Subclinical Antibody–Mediated Kidney Allograft Injury. Transplantation. 2016;100: 2194–2202. doi: 10.1097/TP.0000000000001012 26636737
Malheiro J, Tafulo S, Dias L, Martins LS, Fonseca I, Beirão I, et al. Determining donor-specific antibodies C1q–binding ability improves the prediction of antibody–mediated rejection in HLA–incompatible kidney transplantation. Transpl Int. 2017;30: 347–359. doi: 10.1111/tri.12873 27717025
Visentin J, Chartier A, Massara L, Linares G, Guidicelli G, Blanchard E, et al. Lung intragraft donor-specific antibodies as a risk factor for graft loss. J Heart Lung Transplant. 2016;35: 1418–1426. doi: 10.1016/j.healun.2016.06.010 27450460
Bamoulid J, Roodenburg A, Staeck O, Wu K, Rudolph B, Brakemeier S, et al. Clinical Outcome of Patients with De Novo C1q–Binding Donor-specific HLA Antibodies after Renal Transplantation: Transplantation. 2017;101: 2165–2174. doi: 10.1097/TP.0000000000001487 27653301
Moktefi A, Parisot J, Desvaux D, Canoui–Poitrine F, Brocheriou I, Peltier J, et al. C1q binding is not an independent risk factor for kidney allograft loss after an acute antibody–mediated rejection episode: a retrospective cohort study. Transpl Int. 2017;30: 277–287. doi: 10.1111/tri.12905 27992962
Sicard A, Meas–Yedid V, Rabeyrin M, Koenig A, Ducreux S, Dijoud F, et al. Computer–assisted topological analysis of renal allograft inflammation adds to risk evaluation at diagnosis of humoral rejection. Kidney Int. 2017;92: 214–226. doi: 10.1016/j.kint.2017.01.011 28318622
Das BB, Lacelle C, Zhang S, Gao A, Fixler D, Complement (C1q) Binding De Novo Donor Specific Antibodies and Cardiac–Allograft Vasculopathy in Pediatric Heart Transplant Recipients. Transplantation. 2018;102(3): 502–509. doi: 10.1097/TP.0000000000001944 28885488
Couchonnal E, Rivet C, Ducreux S, Dumortier J, Bosch A, Boillot O, et al. Deleterious impact of C3d–binding donor-specific anti-HLA antibodies after pediatric liver transplantation. Transpl Immunol. 2017;45: 8–14. doi: 10.1016/j.trim.2017.08.001 28782692
Bailly E, Anglicheau D, Blancho G, Gatault P, Vuiblet V, Chatelet V, et al. Prognostic Value of the Persistence of C1q–Binding Anti-HLA Antibodies in Acute Antibody–Mediated Rejection in Kidney Transplantation. Transplantation. 2018;102: 688–698. doi: 10.1097/TP.0000000000002002 29135832
Molina J, Navas A, Agüera M–L, Rodelo–Haad C, Alonso C, Rodríguez–Benot A, et al. Impact of Preformed Donor-specific Anti–Human Leukocyte Antigen Antibody C1q–Binding Ability on Kidney Allograft Outcome. Front Immunol. 2017;8: 1310. doi: 10.3389/fimmu.2017.01310 29163462
Global Observatory on Donation and Transplantation. [Cited 1 January 2018]. Available from: http://www.transplant-observatory.org/.
Tyan DB, Application, technical issues, and interpretation of C1q for graft outcome. Curr Opin Organ Transplant. 2017;22: 505–510. doi: 10.1097/MOT.0000000000000454 28723698
Tambur AR, Herrera ND, Haarberg KMK, Cusick MF, Gordon RA, Leventhal JR, et al. Assessing Antibody Strength: Comparison of MFI, C1q, and Titer Information. Am J Transplant. 2015;15: 2421–2430. doi: 10.1111/ajt.13295 25930984
Hönger G, Amico P, Arnold M–L, Spriewald BM, Schaub S, Effects of weak/non–complement–binding HLA antibodies on C1q–binding. HLA. 2017;90: 88–94. doi: 10.1111/tan.13062 28585289
Boekholdt SM, Arsenault BJ, Mora S, Pedersen TR, LaRosa JC, Nestel PJ, et al. Association of LDL cholesterol, non–HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis. JAMA. 2012;307: 1302–1309. doi: 10.1001/jama.2012.366 22453571
Zhang Y, Guan D–H, Bi R–X, Xie J, Yang C–H, Jiang Y–H, Prognostic value of microRNAs in gastric cancer: a meta-analysis. Oncotarget. 2017;6: 2849–2863. doi: 10.18632/oncotarget.18590
Kivimäki M, Kuosma E, Ferrie JE, Luukkonen R, Nyberg ST, Alfredsson L, et al. Overweight, obesity, and risk of cardiometabolic multimorbidity: pooled analysis of individual–level data for 120 813 adults from 16 cohort studies from the USA and Europe. Lancet Public Health. 2017;2: e277–e285. doi: 10.1016/S2468-2667(17)30074-9 28626830
Emerging Risk Factors CollaborationKaptoge S, Di Angelantonio E, Lowe G, Pepys MB, Thompson SG, et al. C–reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet. 2010;375: 132–140. doi: 10.1016/S0140-6736(09)61717-7 20031199
Vo AA, Zeevi A, Choi J, Cisneros K, Toyoda M, Kahwaji J, et al. A phase I/II placebo–controlled trial of C1–inhibitor for prevention of antibody–mediated rejection in HLA sensitized patients. Transplantation. 2015;99: 299–308. doi: 10.1097/TP.0000000000000592 25606785
Viglietti D, Gosset C, Loupy A, Deville L, Verine J, Zeevi A, et al. C1 Inhibitor in Acute Antibody–Mediated Rejection Nonresponsive to Conventional Therapy in Kidney Transplant Recipients: A Pilot Study. Am J Transplant. 2016;16: 1596–603. doi: 10.1111/ajt.13663 26693703
Jordan SC, Lorant T, Choi J, Kjellman C, Winstedt L, Bengtsson M, et al. IgG Endopeptidase in Highly Sensitized Patients Undergoing Transplantation. N Engl J Med. 2017;377: 442–453. doi: 10.1056/NEJMoa1612567 28767349
Kulkarni S, Kirkiles–Smith NC, Deng YH, Formica RN, Moeckel G, Broecker V, et al. Eculizumab Therapy for Chronic Antibody–Mediated Injury in Kidney Transplant Recipients: A Pilot Randomized Controlled Trial. Am J Transplant. 2017;17: 682–691. doi: 10.1111/ajt.14001 27501352
Lefaucheur C, Viglietti D, Hidalgo LG, Ratner LE, Bagnasco SM, Batal I, et al. Complement-activating Anti-HLA Antibodies in Kidney Transplantation: Allograft Gene Expression Profiling and Response to Treatment. J Am Soc Nephrol. 2018;29: 620–635. doi: 10.1681/ASN.2017050589 29042454